TY - JOUR T1 - The Transient Receptor Potential Vanilloid-1 Channel in Thermoregulation: A Thermosensor It Is Not JF - Pharmacological Reviews JO - Pharmacol Rev DO - 10.1124/pr.109.001263 SP - pr.109.001263 AU - Andrej A. Romanovsky AU - Maria C. Almeida AU - Andras Garami AU - Alexandre A. Steiner AU - Mark H. Norman AU - Shaun F. Morrison AU - Kazuhiro Nakamura AU - Jeffrey J. Burmeister AU - Tatiane B. Nucci Y1 - 2009/09/11 UR - http://pharmrev.aspetjournals.org/content/early/2009/09/11/pr.109.001263.abstract N2 - The development of antagonists of the transient receptor potential vanilloid-1 (TRPV1) channel as pain therapeutics has revealed that these compounds cause hyperthermia in humans. This undesirable on-target side effect has triggered a surge of interest in the role of TRPV1 in thermoregulation and revived the hypothesis that TRPV1 channels serve as thermosensors. We review literature data on the distribution of TRPV1 channels in the body and on thermoregulatory responses to TRPV1 agonists and antagonists. We propose that two principal populations of TRPV1-expressing cells have connections with efferent thermoeffector pathways: 1) first-order sensory (polymodal), glutamatergic dorsal-root (and possibly nodose) ganglia neurons that innervate the abdominal viscera and 2) higher-order sensory, glutamatergic neurons presumably located in the median preoptic hypothalamic nucleus. We further hypothesize that all thermoregulatory responses to TRPV1 agonists and antagonists and thermoregulatory manifestations of TRPV1 desensitization stem from primary actions on these two neuronal populations. Agonists act primarily centrally on population 2; antagonists act primarily peripherally on population 1. We analyze what roles TRPV1 might play in thermoregulation and conclude that this channel does not serve as a thermosensor, at least not under physiological conditions. In the hypothalamus, TRPV1 channels are inactive at common brain temperatures. In the abdomen, TRPV1 channels are tonically activated, but not by temperature. However, tonic activation of visceral TRPV1 by nonthermal factors suppresses autonomic cold-defense effectors and, consequently, body temperature. Blockade of this activation by TRPV1 antagonists disinhibits thermoeffectors and causes hyperthermia. Strategies for creating hyperthermia-free TRPV1 antagonists are outlined. The potential physiological and pathological significance of TRPV1-mediated thermoregulatory effects is discussed. ©2009 The American Society for Pharmacology and Experimental Therapeutics ER -